The OPTION trial: inhibition of the interleukin-6 receptor with tocilizumab in patients with rheumatoid arthritis

By Ramos-Remus Cesar   Muriel-Vizcaino Rodolfo  

Future Rheumatology, Vol. 3, Iss. 5, 2008-10 ,pp. : 429-434

Future Medicine

Access to resources Recommend Favorite

Rituximab therapy for HIV-associated multicentric Castleman disease

By Veraitch Ophelia   Bower Mark   Shackleton David   Stebbing Justin  

HIV Therapy, Vol. 4, Iss. 3, 2010-05 ,pp. : 281-284

Future Medicine

Access to resources Recommend Favorite

The efficacy of tocilizumab in a patient with pulmonary arterial hypertension associated with Castleman’s disease

By Arita Yoh   Sakata Yasushi   Sudo Takao   Maeda Tetsuo   Matsuoka Ken   Tamai Keito   Higuchi Kaori   Shioyama Wataru   Nakaoka Yoshikazu   Kanakura Yuzuru   Yamauchi-Takihara Keiko  

Heart and Vessels, Vol. 25, Iss. 5, 2010-09 ,pp. : 444-447

Springer Publishing Company

Access to resources Recommend Favorite

Therapeutic Implications of Tocilizumab, A Humanized Anti-Interleukin-6 Receptor Antibody, for Various Immune-Mediated Diseases: An Update Review

By  

Current Rheumatology Reviews, Vol. 8, Iss. 3, 2012-08 ,pp. : 209-226

Bentham Science Publishers

Access to resources Recommend Favorite

A case of Behçet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab

By Hirano Toru  

Modern Rheumatology, Vol. 22, Iss. 2, 2012-04 ,pp. : 298-302

Springer Publishing Company

Access to resources Recommend Favorite